Acumen Pharmaceuticals, Inc. (ABOS) Dividend History

Acumen Pharmaceuticals, Inc. (ABOS) is a biotechnology company focused on developing therapies for neurodegenerative diseases, particularly Alzheimer’s disease. The company emphasizes innovative approaches to address the underlying causes of cognitive decline, aiming to improve patient outcomes through its research and development efforts in the neurodegeneration space.

427 Park St., Charlottesville, VA, 22902
Phone: 925-368-8508
Website: https://www.acumenpharm.com

Dividend History

Acumen Pharmaceuticals, Inc. currently does not pay dividends

Company News

  • Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences

    Acumen Pharmaceuticals will participate in two upcoming investor conferences in September 2025, presenting its ongoing research into Alzheimer's disease treatment using sabirnetug (ACU193), a monoclonal antibody targeting toxic amyloid beta oligomers.

    GlobeNewswire Inc.
    Featured Companies: HALO
  • 4 High-Risk, High-Reward Small-Cap Stocks to Play the Rotation - Investing.com

    The article discusses four small-cap stocks that offer high risk and high reward potential as investors rotate their portfolios. The stocks are from the biotech and electric vehicle sectors, with analysts seeing significant upside but also inherent risks.

    Investing.com
    Featured Companies: BLNK ELDN
  • Why Acumen Pharmaceuticals (ABOS) Stock Might be a Great Pick

    Acumen Pharmaceuticals (ABOS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

    Zacks Investment Research
  • $40M Bet On Acumen Pharmaceuticals? Check Out These 3 Stocks Insiders Are Buying

    Although US stocks closed higher on Tuesday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision. Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform. Acumen Pharmaceuticals The Trade: Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) Director Rajeev Shah ...

    Benzinga
    Featured Companies: BHLB CULP
  • Why Shares of Acumen Pharmaceuticals Are Down Tuesday

    The company announced a $100 million stock sale.

    The Motley Fool
Page data last updated 09/07/2025 09:08:10 UTC